ReviewNanoscale advances2020
Role of inorganic nanoparticle degradation in cancer therapy.
Review in Nanoscale advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- Engineering combination nanomedicines to overcome cancer resistance.RSC advances · 2026Review
- Multifunctional vesicles in cancer therapy and theranostics: current advances and future challenges.Journal of nanobiotechnology · 2025Review
- Tumor cell membrane-based vaccines: A potential boost for cancer immunotherapy.Exploration (Beijing, China) · 2024Review
- Silver nanoparticle induced immunogenic cell death can improve immunotherapy.Journal of nanobiotechnology · 2024Article
- Breaking barriers: The potential of nanosystems in antituberculosis therapy.Bioactive materials · 2024Review
- Phage-based delivery systems: engineering, applications, and challenges in nanomedicines.Journal of nanobiotechnology · 2024Review
- Aluminum enhances the oxidative damage of ZnO NMs in the human neuroblastoma SH-SY5Y cell line.Discover nano · 2024Article
- The development of ZnO nanoparticle-embedded graphitic-carbon nitride towards triple-negative breast cancer therapy.RSC advances · 2023Article
- Cu-doped TiOJournal of nanobiotechnology · 2023Article
- Nanotechnology-based diagnostics and therapeutics in acute lymphoblastic leukemia: a systematic review of preclinical studies.Nanoscale advances · 2023Review
- Protein nanoparticles directed cancer imaging and therapy.Nano convergence · 2022Review
- Enhancement of fluorescence and anti-tumor effect of ZnO QDs by La doping.Frontiers in chemistry · 2022Article
- ROS Modulating Inorganic Nanoparticles: A Novel Cancer Therapeutic Tool.Recent advances in drug delivery and formulation · 2022Article
- Mechanisms of immune response to inorganic nanoparticles and their degradation products.Advanced drug delivery reviews · 2022Review
- Prospects of Cationic Carbosilane Dendronized Gold Nanoparticles as Non-viral Vectors for Delivery of Anticancer siRNAs siBCL-xL and siMCL-1.Pharmaceutics · 2021Article
- Characterization and Optimization of Chitosan-Coated Polybutylcyanoacrylate Nanoparticles for the Transfection-Guided Neural Differentiation of Mouse Induced Pluripotent Stem Cells.International journal of molecular sciences · 2021Article
- Laser-induced thermal response and controlled release of copper oxide nanoparticles from multifunctional polymeric nanocarriers.Science and technology of advanced materials · 2021Article
- Structure and luminescence of DNA-templated silver clusters.Nanoscale advances · 2021Review
- The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.Chemical reviews · 2021Review
- Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics.Frontiers in chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomaterials are currently widely exploited for their potential in the development of novel cancer therapies, and so far, mainly nanoparticles (NPs) consisting of liposomes and polymers have made their way into the clinic. However, major bottlenecks for the clinical translation of other types of NPs (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.